Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Intas Pharmaceuticals announces European Commission approval and completion of its purchase of an Out-licensing basket of products from TEVA

Intas Pharmaceuticals
Posted on: 02 Mar 18

Intas Pharmaceuticals is pleased to announce EC approval has been granted for its purchase of rights to a portfolio of 12 products from TEVA.  

This transaction forms part of the European Commission’s (EC) anti-trust divestiture requirements arising from TEVA’s acquisition of Allergan’s generics business, more commonly referred to as the ‘Out-licensing Basket’ and is one of the “baskets” acquired by Intas Group from TEVA. Completion of this transaction follows completion of Accord Healthcare’s acquisition of the Actavis UK & IE business from TEVA in January 2017.

The deal includes the rights to 12 products, together with the associated supply contracts to a platform of more than 25 different customers in the European Union. This business was formerly led by Teva’s out-licensing unit Medis.  

The products included in the basket are Acetylsalicylic acid, Alendronic acid, Ipatropium+Salbutamol, Lisinopril, Oxaliplatin lyophilized and liquid, Risedronic acid, Triamterene+HCTZ, Nifedipine, Benazepril, Benazepril+HCTZ and Quinapril+HCTZ.

Marc Comas, EVP-Global Licensing and Third Party Sales for Intas said: “Our vision is to become one of the most active players in the Out-licensing & B2B of pharmaceuticals in Europe. With this acquisition, we add a basket of new products to our already broad portfolio and reinforce our strong positioning in the out-licensing business. On top of that, we will also enlarge our platform of partnerships throughout the European market.”

Editor's Details

Hayley Jayawardene
Hayley Jayawardene Limited

Last updated on: 02/03/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.